Other conditions.

Early-stage work across OCD, eating disorders, headache and chronic pain. Almost everything here is a pilot with fewer than 20 people and no control group. Treat it as a list of open questions.

9 studies · 6 early · 3 moderate

eating disordersMicro + fullBothModerate evidence

Twenty-one women with anorexia, and symptoms that improved for a year

The largest psilocybin study in anorexia so far, and the safety event it reported honestly.2026 / Single-blind within-individual pilot study / 21 peopleRead it

OCDMicro + fullBothModerate evidence

One small trial is the entire case for psilocybin and OCD

A review finds one small trial and a trail of case reports going back to the sixties.2024 / Narrative review / Review of existing literatureRead it

OCDMicro + fullBothEarly signal

Nine people with OCD, and symptoms that dropped within hours

The only real trial that exists, and it is nearly twenty years old.2006 / Small modified double-blind dose-escalation study / 9 peopleRead it

cluster headacheFull doseFullModerate evidence

Cluster headaches dropped on psilocybin, but not significantly

A large-looking drop in attacks that did not reach significance.2022 / Randomised double-blind placebo-controlled exploratory trial / 30 enrolledRead it

migraineFull doseFullEarly signal

Migraine days halved, and not because of the trip

The size of the reduction had nothing to do with how intense the experience was.2021 / Exploratory double-blind placebo-controlled crossover study / 10 peopleRead it

eating disordersFull doseFullEarly signal

Ten women with anorexia, and psilocybin looked safe to give

Ten women, and a trial designed to test safety rather than benefit.2023 / Phase 1 open-label feasibility study / 10 peopleRead it

body dysmorphiaFull doseFullEarly signal

Seven of twelve with body dysmorphia responded to one dose

Seven of twelve people responded to a single dose.2023 / Open-label pilot trial / 12 peopleRead it

PTSDFull doseFullEarly signal

Twenty-two people with PTSD, and a large drop with no control

Twenty-two people, no control group, and a large symptom drop.2026 / Phase 2 nonrandomised open-label multicentre trial / 22 peopleRead it

chronic painFull doseFullEarly signal

Five people with fibromyalgia, and pain that eased at a month

Large effect sizes, and a sample far too small to trust them.2025 / Open-label pilot clinical trial / 5 peopleRead it

We include the trials that missed their endpoints alongside the ones that hit. A shelf that only holds good news is a marketing page, not a library.

More research areas

Microdosing 8 Depression 9 Anxiety 6 Addiction 9 Cognition 6 Ageing and injury 3 Brain and plasticity 7 Safety 6 All research 63

For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.